The pandemic is out of control.
The world is up to 67 million cases, with 1.53 million unfortunate deaths. In the U.S., the case count is now up to 14.7 million. India is nearly 9.7 million.
“The vaccine is critical, but it’s not going to save us from this current surge. Only we can save us from this current surge. And we know precisely what to do,” Dr. Deborah Birx, the White House CV-19 response coordinator said, as quoted by The New York Post., adding the “fall/winter surge is combining everything that we saw in this spring with everything that we saw in the summer, plus the fall surge going into a winter surge.”
Cities are closing down to cool the spread. Hospitals are being overwhelmed. In fact, some nurses say the virus is pushing hospitals to the brink of rationing care.
The Centers for Disease Control and Prevention issued its strongest call for masks, urging Americans to wear masks indoors when not at home.
But we may be closer to seeing a vaccine, and emergency use authorization this week and next – which could help create a big upside opportunity for these three top vaccine stocks.
For one, Moderna (MRNA) expects an emergency use nod for its vaccine shortly after its Dec. 17 meeting with the US FDA.
Two, Pfizer (PFE) and BioNTech (BNTX) could run higher this week.
All after the US FDA said its vaccine is safe and effective after one dose.
“The information was made public before a meeting Thursday of the Vaccines and Related Biological Products Advisory Committee — an advisory group to the FDA that will vote on whether to advise the agency to grant emergency use authorization of the vaccine in the U.S.,” as reported by NBC News.
The post The Top 3 Vaccine Stocks to Consider Immediately appeared first on Morningology.
